{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:55:15Z","timestamp":1782219315014,"version":"3.54.5"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA), a renin-independent state of aldosterone excess, is associated with excess risk of stroke, myocardial infarction, atrial fibrillation, heart failure, and chronic kidney disease compared with essential hypertension. Emerging evidence suggests that renin-independent aldosterone excess exists on a continuum rather than as a dichotomous disease state, including subclinical primary aldosteronism (sPA), even in normotensive individuals. Whether sPA is associated with major adverse cardiovascular events (MACE) prior to overt hypertension remains incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize available evidence linking renin suppression and mild aldosterone excess to cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of the literature was conducted using PubMed\/MEDLINE, the Cochrane Library, and Web of Science from inception through May 2025, to identify cohort studies evaluating renin phenotype, aldosterone levels, and cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Suppressed renin and higher aldosterone levels, even within conventionally normal ranges, are associated with incident hypertension, left ventricular hypertrophy (LVH), atrial fibrillation, and cardiovascular events. In overt PA, significantly higher rates of cardiovascular diseases have been observed compared with blood pressure-matched essential hypertension. Emerging population-based data suggest a graded cardiovascular risk extending below traditional diagnostic thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biochemical phenotypes consistent with sPA may represent an early cardiometabolic state associated with elevated risk of MACE, even before overt PA criteria are met. The absence of standardized diagnostic thresholds and randomized interventional data currently limits clinical translation. Prospective trials evaluating renin-guided screening and early mineralocorticoid receptor antagonism are needed to determine whether intervention at the subclinical stage reduces long-term cardiovascular harm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1826678","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:34:08Z","timestamp":1782218048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subclinical primary aldosteronism and major adverse cardiovascular events: evidence for a continuum of renin-independent aldosterone excess and a proposal for early detection"],"prefix":"10.3389","volume":"13","author":[{"given":"Atef","family":"Akoum","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hennepin Healthcare","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Hakim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Kwayess","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Endocrinology and Metabolism, Indiana University","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa El Deen","family":"Wehbeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Alaaeddine","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Nasser","family":"El Shabrawi","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Aswan Heart Center, Magdi Yacoub Foundation","place":["Aswan, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashesh","family":"Das","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, New York University Langone Health","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekant","family":"Avula","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University of Minnesota","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Rebeiz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Massachusetts Chan Medical School","place":["Worcester, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/ijms26020540","article-title":"Non-hypertensive effects of aldosterone","volume":"26","author":"Ekman","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1042\/EBC20210006","article-title":"Mineralocorticoid receptor actions in cardiovascular development and disease","volume":"65","author":"Young","year":"2021","journal-title":"Essays Biochem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1677\/JME-08-0144","article-title":"Corticosteroid receptors, macrophages and cardiovascular disease","volume":"42","author":"Rickard","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1210\/en.2011-2098","article-title":"Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis","volume":"153","author":"Bienvenu","year":"2012","journal-title":"Endocrinology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3390\/ijms24065370","article-title":"The effect of aldosterone on cardiorenal and metabolic systems","volume":"24","author":"Otsuka","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102791","DOI":"10.1016\/j.cpcardiol.2024.102791","article-title":"Global and regional prevalence and cardiovascular risk of primary aldosteronism: a systematic review and meta-analysis","volume":"49","author":"Huang","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","article-title":"Subclinical primary aldosteronism and Major adverse cardiovascular events: a longitudinal population-based cohort study","volume":"152","author":"Goupil","year":"2025","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.beem.2011.11.006","article-title":"Subclinical primary aldosteronism","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0140-6736(75)91814-0","article-title":"Plasma renin and blood pressure","volume":"305","author":"Adlin","year":"1975","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism: a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1055\/s-0043-122394","article-title":"Aldosterone-producing cell clusters in normal and pathological states","volume":"49","author":"Omata","year":"2017","journal-title":"Horm Metab Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among US veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"key":"B22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","article-title":"Outcomes of a specialized clinic on investigation and treatment of primary aldosteronism","volume":"156","author":"Liu","year":"2021","journal-title":"JAMA Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1002\/j.2040-4603.2023.tb00256.x","article-title":"Aldosterone: renal action and physiological effects","volume":"13","author":"Johnston","year":"2023","journal-title":"Compr Physiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000320387","article-title":"High-salt diet and hypertension: focus on the renin-angiotensin system","volume":"34","author":"Drenjan\u010devi\u0107-Peri\u0107","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.120.16440","article-title":"Altered taste perception for sodium chloride in patients with primary aldosteronism","volume":"77","author":"Adolf","year":"2021","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/01.HYP.24.1.30","article-title":"Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension","volume":"24","author":"Robert","year":"1994","journal-title":"Hypertension"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105427","DOI":"10.1016\/j.neubiorev.2023.105427","article-title":"Role of aldosterone and mineralocorticoid receptor in addiction: a scoping review","volume":"154","author":"Pince","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"H190","DOI":"10.1152\/ajpheart.00622.2006","article-title":"Aldosterone impairs baroreflex sensitivity in healthy adults","volume":"292","author":"Monahan","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"801689","DOI":"10.3389\/fendo.2021.801689","article-title":"The role of aldosterone in OSA and OSA-related hypertension","volume":"12","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy in resistant hypertension and hyperaldosteronism","volume":"55","author":"Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.jfma.2023.04.019","article-title":"Aldosterone-to-renin ratio as screening tool for primary aldosteronism","volume":"123","author":"Lin","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrationsin primary aldosteronism","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.31688\/ABMU.2024.59.4.11","article-title":"Primary hyperaldosteronism: an underdiagnosed syndrome","volume":"59","author":"Kecaj","year":"2024","journal-title":"Arch Balk Med Union"},{"key":"B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/jch.14740","article-title":"Redefining primary hyperaldosteronism as syndrome of inappropriate aldosterone secretion (SIALDS)\u201d: a common but unrecognized cause of hypertension","volume":"25","author":"Lamba","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1210\/clinem\/dgab348","article-title":"Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism","volume":"106","author":"Hung","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.124.22884","article-title":"Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism","volume":"81","author":"Marcelli","year":"2024","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"Unrecognized prevalence of primary aldosteronism","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1365-2362.2012.02676.x","article-title":"Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances","volume":"42","author":"Galuppo","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1016\/j.ijcard.2013.08.027","article-title":"Myocardial fibrosis and QTc reduction following spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial","volume":"168","author":"Wong","year":"2013","journal-title":"Int J Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/14656566.2018.1476489","article-title":"Managing cardiovascular disease and sleep apnea with pharmacotherapy","volume":"19","author":"Wolf","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1210\/clinem\/dgac649","article-title":"Implication of MR activity in posttreatment arterial stiffness reversal in patients with primary aldosteronism","volume":"108","author":"Chen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"B47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/a-1141-5989","article-title":"Atrial fibrillation in primary aldosteronism","volume":"52","author":"Pan","year":"2020","journal-title":"Horm Metab Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/clc.20914","article-title":"Effect of spironolactone on atrial fibrillation in structural heart disease","volume":"34","author":"Williams","year":"2011","journal-title":"Clin Cardiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-Term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"key":"B54","doi-asserted-by":"publisher","first-page":"bvab174","DOI":"10.1210\/jendso\/bvab174","article-title":"Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin","volume":"6","author":"Saiki","year":"2022","journal-title":"J Endocr Soc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1826678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:34:09Z","timestamp":1782218049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1826678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":54,"alternative-id":["10.3389\/fcvm.2026.1826678"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1826678","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1826678"}}